Skip to main content
. 1997 Jan 21;94(2):679–683. doi: 10.1073/pnas.94.2.679

Figure 2.

Figure 2

The PARS inhibitor 3-AB attenuates the contractile dysfunction and reduces infarct size of hearts subjected to global ischemia and reperfusion. Thirty minutes of global ischemia followed by 2 h of reperfusion (▪, vehicle control, n = 7) resulted in (a) a substantial impairment of left ventricular developed pressure (LVDP) and (b) a rise in left ventricular end diastolic pressure (LVEDP) in the isolated, perfused heart of the rabbit. Infusion (into the perfusion buffer) of 3-AB (□, final concentration 100 μM, n = 6) resulted in a significant improvement in the recovery of contractile function and attenuated the rise in LVEDP. ∗, P < 0.05, ANOVA followed by Bonferoni’s test when compared with vehicle control. (c) When compared with control (open column, n = 7), 3-AB (solid column, n = 6) caused a significant reduction in infarct size.